Navigation Links
Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Date:8/24/2009

BEDFORD, MA August, 24, 2009 -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome. In this 28-day, randomized, placebo-controlled, 232-patient trial, RX-10045 produced dose-dependent, statistically significant improvement on the primary endpoints for both the signs and symptoms of dry eye, and was generally shown to be safe and well tolerated. These Phase 2 results represent the first demonstration of clinical efficacy for the novel class of resolvin compounds and suggest that resolvins have the potential to treat a broad range of inflammatory diseases.

"There is an urgent need for new treatment options in dry eye and the results of this Phase 2 study are as strong as any I have seen," said Stephen Pflugfelder, MD, an expert in dry eye at Baylor College of Medicine. "Based both on these clinical results and on its unique mode of action, I am confident that RX-10045 can be an important new treatment modality for these patients."

The 28-day, randomized, multi-center, placebo-controlled study in 232 patients with moderate dry eye patients was designed to evaluate the safety, tolerability and efficacy of RX-10045 administered twice daily. The Phase 2 study examined three doses of RX-10045 and utilized a controlled adverse environment (CAE) to measure corneal staining in a stressful drying environment, as well as daily patient diaries using a standard visual analog scale to assess symptom improvement over the course of the study.

RX-10045 produced a significant dose-dependent improvement from baseline in symptoms recorded in daily patient diaries. The improvement was observed across all symptoms evaluated in the study, including dryness, stinging, burning, grittiness, ocular discomfort and the composite of each patient's most sev
'/>"/>

Contact: Kathryn Morris
kathryn@kmorrispr.com
845-635-9828
Yates Public Relations
Source:Eurekalert

Page: 1 2

Related biology news :

1. delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
2. BIO-key(R) Announces Second Quarter Conference Call Schedule
3. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
4. BIO-key(R) Announces Second Quarter Conference Call Schedule
5. Obama administration announces more than $327 million in Recovery Act funding for science research
6. delSECUR CORPORATION Announces Agreement to Purchase the Intellectual Property Assets of the Corporation
7. SRI announces selection by the National Cancer Institute as a Chemical Biology Consortium center
8. IOS Press announces launch of Journal of Berry Research
9. Aware, Inc. Announces Q209 Earnings Conference Call
10. Supply-Chain Council Announces New Board of Directors and Officers
11. Ecological Society of America announces 2009 award recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... landmark study aimed at improving the food intake, health ... care homes is among three projects at the University ... from the Canadian Institutes of Health Research (CIHR). ... Health Sciences at Waterloo, and a Schlegel research chair ... years to investigate why many Canadians living in long-term ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Journal of Animal Science , researchers evaluated how different levels ... to the researchers, the effects of selenium supplementation on the ... extensively in horses. Dr. Laurie Lawrence, animal science professor ... in soil and forages varies across the United States. She ...
... of consuming omega-3 long chain polyunsaturated fatty acids such ... sources of these fatty acids in the human diet ... of Saskatchewan, Department of Animal and Poultry Science are ... of farmed fish. As wild fish stocks ...
... reporting "a significant step forward" in proving the feasibility of ... for exotic new life forms. Their description of successful deployment ... seafloor lander equipped with a mini-laboratory the size of a ... of DNA in the deep oceans appears in ACS, ...
Cached Biology News:Researchers study selenium's effects on horses 2
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies Corp. ... developing first in class collagenase-based products marketed as ... in the U.S. and XIAPEX ® in ... from a randomized, double-blind Phase 2a study of ... edematous fibrosclerotic panniculopathy. The results showed that all ...
(Date:8/21/2014)... research team including DESY scientists has observed tiny quantum ... reports in the journal Science that the ... the nanodroplets. It is the first time that the ... samples of what is known as superfluid helium, have ... best expectations," says Andrey Vilesov of the University of ...
(Date:8/21/2014)... IA (PRWEB) August 21, 2014 His ... LIBERTY Opening , The Court of His Majesty Willem-Alexander, ... will attend the Grand Opening of POET-DSM Advanced Biofuels’ ... Wednesday, Sept. 3. , The King will take part ... opening activity, scheduled for 11 a.m.-12:20 p.m. and tour ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Scientists observe quantum vortices in cold helium droplets 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3
... Fla., April 14 Phlo Corporation,(Pink Sheets: PHCP) ... stock certificates are negotiable in connection with,market transactions ... current,position in Phlo common stock. This clarification was ... number of brokers and clearing firms,will not negotiate ...
... in the second quarter of 2008 ... ... Ardea,Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data ... compounds demonstrating potent,activity against the human-immunodeficiency virus (HIV), including NNRTI-,resistant strains, with ...
... basis of blood-based ColonSentry(TM) test -, TORONTO, ... company focused on developing blood-based biomarker tests for ... today reported,positive performance results from a large validation ... of a patient,s current risk for,colorectal cancer. This ...
Cached Biology Technology:Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 2Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses 3GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... Jouan B4i ventilated and BR4i refrigerated multifunction centrifuges ... speed operation at a low sound level with ... for biocontainment. Their AUTO-LOCK rotor exchange system without ... for use within seconds. Instant rotor ...
... ventilated and BR4i refrigerated multifunction centrifuges are equally ... at a low sound level with a large ... Their AUTO-LOCK rotor exchange system without tools ensures ... within seconds. Instant rotor exchange (5 ...
Biology Products: